BRIEF published on 04/29/2026 at 13:05, 7 days 18 hours ago Cheplapharm Sees Revenue Growth in 2025 Pharmaceutical Industry Revenue Growth EBITDA Margin Financial Stability CHEPLAPHARM
PRESS RELEASE published on 04/29/2026 at 13:00, 7 days 18 hours ago CHEPLAPHARM reports Revenue Growth in the 2025 Financial Year CHEPLAPHARM reports 8.1% revenue growth reaching €1.66 billion in FY2025. EBITDA at €642.8 million with a 38.8% margin. Employee count up 2% to 799 Financial Results EBITDA Revenue Growth CHEPLAPHARM Employee Count
BRIEF published on 02/02/2026 at 15:41, 3 months 4 days ago CHEPLAPHARM's Successful €950m Bond Issuance Refinancing Bond Issuance Financial Strategy Investor Demand CHEPLAPHARM
PRESS RELEASE published on 02/02/2026 at 15:36, 3 months 4 days ago Successful Refinancing: CHEPLAPHARM'S new 6.750% Bond multiple times oversubscribed CHEPLAPHARM successfully refinances with new 6.750% bond oversubscribed multiple times, enhancing financial flexibility and maturity profile Refinancing Oversubscribed Financial Flexibility CHEPLAPHARM 6.750% Bond
BRIEF published on 08/27/2025 at 13:34, 8 months 10 days ago CHEPLAPHARM Reports Stable Growth in the First Half of 2025 Pharmaceutical Industry Revenue Growth Transformation Program CHEPLAPHARM Employee Expansion
PRESS RELEASE published on 08/27/2025 at 13:29, 8 months 10 days ago CHEPLAPHARM with stable business in the first half of 2025 Cheplapharm AG reports stable business performance in the first half of 2025, with revenue up by 12% and EBITDA up by 24% compared to the second half of 2024 Financial Results Transformation Program Stability Acquisition Opportunities Cheplapharm AG
BRIEF published on 06/26/2025 at 10:36, 10 months 10 days ago CHEPLAPHARM's €750M Bond Sees High Demand and Attractive Pricing Pharmaceuticals Investor Confidence Financial Flexibility Bonds CHEPLAPHARM
PRESS RELEASE published on 06/26/2025 at 10:31, 10 months 10 days ago High Demand and Attractive Pricing: CHEPLAPHARM's New 7.125% Bond Multiple Times Oversubscribed CHEPLAPHARM successfully places €750m senior secured notes at 7.125% interest rate, enhancing financial flexibility and extending maturity profile, oversubscribed transaction Senior Secured Notes Oversubscribed Financial Flexibility CHEPLAPHARM 7.125%
BRIEF published on 06/02/2025 at 10:34, 11 months 4 days ago Sandra Schröder Joins CHEPLAPHARM as VP Scientific Pharmaceutical Regulatory Affairs Quality Management CHEPLAPHARM Sandra Schröder
PRESS RELEASE published on 06/02/2025 at 10:29, 11 months 4 days ago Sandra Schröder joins CHEPLAPHARM’S Management Team as VP Scientific Sandra Schröder appointed as VP Scientific at CHEPLAPHARM, responsible for scientific areas globally. Brings 25 years of experience from F. Hoffmann-La Roche AG Pharmaceutical Industry Management CHEPLAPHARM Sandra Schröder VP Scientific
Published on 05/07/2026 at 05:40, 1 hour 58 minutes ago New Horizon Aircraft Ltd. Announces Pricing of $20 Million Offering of Common Shares
Published on 05/07/2026 at 02:00, 5 hours 38 minutes ago Lobe Sciences Ltd. Announces Participation in the D. Boral Capital Global Conference in New York
Published on 05/06/2026 at 23:30, 8 hours 8 minutes ago Stabilis Solutions Announces First Quarter 2026 Results
Published on 05/06/2026 at 23:05, 8 hours 33 minutes ago Zomedica Announces Record First Quarter Revenue of $8.8 Million, Reflecting 35% Annual Growth; and $47.5 Million in Liquidity
Published on 05/06/2026 at 23:00, 8 hours 38 minutes ago Green Bridge Metals Strengthens Technical and Strategic Team as 2026 Work Programs Advance
Published on 05/07/2026 at 07:15, 23 minutes ago DITP unveils 'Reimagining Thailand' Vision at Thai Night Cannes 2026, Positioning Thailand as a Future Global Content Partner
Published on 05/07/2026 at 07:05, 33 minutes ago EDAG Group achieves positive EBIT in the first quarter of 2026
Published on 05/07/2026 at 07:03, 35 minutes ago SAF-HOLLAND reports robust earnings growth and strong cash flow amid improved demand momentum in the first quarter of 2026
Published on 05/07/2026 at 07:01, 37 minutes ago Swiss Re delivers a net income of USD 1.5 billion for the first quarter
Published on 05/07/2026 at 07:00, 38 minutes ago Good Start into the Year – Confident for 2026 Guidance and 2028 Growth and Deleveraging Objectives
Published on 05/06/2026 at 18:00, 13 hours 38 minutes ago Access to information in respect of the General Shareholders’ Meeting to be held on June 4, 2026
Published on 05/06/2026 at 18:00, 13 hours 38 minutes ago Information concerning the total number of voting rights and shares in the share capital as of April 30, 2026
Published on 05/06/2026 at 17:45, 13 hours 53 minutes ago Information concerning the total number of voting rights and shares 2026 04 30
Published on 05/06/2026 at 17:45, 13 hours 53 minutes ago Declaration of voting rights at the end of April 2026
Published on 05/06/2026 at 17:45, 13 hours 53 minutes ago Accor - Information regarding availability and consultation of preparatory documents - Shareholders' Meeting of May 27, 2026
